Montefusco A, et al. - Self-expandable, sirolimus-eluting Stentys stents (SES) and second-generation drug-eluting stents (DES-II) were compared for their effectiveness and safety in treating the unprotected left main (ULM). They analyzed 151 patients who received SES and 1,270 who received DES-II from the multicenter SPARTA (clinicaltrials.gov: NCT02784405) and FAILS2 registries. At an intermediate-term follow-up, outcomes revealed similar major adverse cardiovascular events (MACE) rate with SES vs DES-II use for ULM treatment. Hence, SES is suggested to be a potential option in this setting.